BACKGROUND: Isolated hepatic perfusion (IHP) involves complete vascular isolation of the liver to allow treatment with doses that would be toxic if delivered systemically. A phase II study of IHP in patients with colorectal metastases confined to the liver was performed. METHODS: Seventy-three patients with irresectable colorectal metastases underwent IHP with high-dose melphalan (200 mg) for 1 h. Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria and tumour response was assessed according to World Health Organization criteria. RESULTS: Seventy-one patients were perfused according to the protocol. Four patients died within 30 days after IHP, resulting in an operative mortality rate of 5.6 per cent. Sixteen patients (22.5 per cent) experienced grade 3-4 hepatotoxicity 1 week after IHP, which was transient and resolved within 3 months in all patients. The tumour response rate (complete or partial remission) was 59 per cent. Median time to progression was 7.7 (range 2.3-31.4) months. Overall median survival after IHP was 28.8 months with a 3-year survival rate of 37 per cent. CONCLUSION: IHP for irresectable colorectal metastases confined to the liver resulted in good response rates and long-term survival in a selected group of patients. Copyright 2003 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
BACKGROUND: Isolated hepatic perfusion (IHP) involves complete vascular isolation of the liver to allow treatment with doses that would be toxic if delivered systemically. A phase II study of IHP in patients with colorectal metastases confined to the liver was performed. METHODS: Seventy-three patients with irresectable colorectal metastases underwent IHP with high-dose melphalan (200 mg) for 1 h. Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria and tumour response was assessed according to World Health Organization criteria. RESULTS: Seventy-one patients were perfused according to the protocol. Four patients died within 30 days after IHP, resulting in an operative mortality rate of 5.6 per cent. Sixteen patients (22.5 per cent) experienced grade 3-4 hepatotoxicity 1 week after IHP, which was transient and resolved within 3 months in all patients. The tumour response rate (complete or partial remission) was 59 per cent. Median time to progression was 7.7 (range 2.3-31.4) months. Overall median survival after IHP was 28.8 months with a 3-year survival rate of 37 per cent. CONCLUSION: IHP for irresectable colorectal metastases confined to the liver resulted in good response rates and long-term survival in a selected group of patients. Copyright 2003 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
Authors: Geert Maleux; Diethard Monbaliu; Chris Verslype; Christophe Casteleyn; Marc Van De Velde; Pieter Cornillie; Yvonne Hoogeveen; Eric Van Cutsem Journal: Eur Radiol Date: 2010-05-22 Impact factor: 5.315
Authors: F Jeroen Vogelaar; Wilma E Mesker; Arjen M Rijken; Gaby W van Pelt; Antonia M van Leeuwen; Hans J Tanke; Rob A Tollenaar; Gerrit J Liefers Journal: BMC Cancer Date: 2010-04-20 Impact factor: 4.430
Authors: Eleonora M de Leede; Mark C Burgmans; Christian H Martini; Fred G J Tijl; Arian R van Erkel; Jaap Vuyk; Ellen Kapiteijn; Cornelis Verhoef; Cornelis J H van de Velde; Alexander L Vahrmeijer Journal: J Vis Exp Date: 2016-07-31 Impact factor: 1.355
Authors: D Magge; A H Zureikat; D L Bartlett; M P Holtzman; H A Choudry; J H Beumer; J F Pingpank; J L Holleran; S Strychor; D E Cunningham; H L Jones; H J Zeh Journal: Ann Surg Oncol Date: 2013-04-11 Impact factor: 5.344
Authors: Cornelis Verhoef; Johannes H W de Wilt; Flavia Brunstein; Andreas W K S Marinelli; Boudewijn van Etten; Maarten Vermaas; Gunther Guetens; Gert de Boeck; Ernst A de Bruijn; Alexander M M Eggermont Journal: Ann Surg Oncol Date: 2008-02-01 Impact factor: 5.344
Authors: Liselot B J van Iersel; Ellen J Hoekman; Hans Gelderblom; Alexander L Vahrmeijer; Els L van Persijn van Meerten; Fred G J Tijl; Henk H Hartgrink; Peter J K Kuppen; Johan W R Nortier; Rob A E M Tollenaar; Cornelis J H van de Velde Journal: Ann Surg Oncol Date: 2008-05-10 Impact factor: 5.344